MOSL initiates Gabriel India with Buy, target ₹1,266; sees 29% upside as company transforms into diversified mobility platformBusiness Upturn• 5m ago
Pharma stocks in focus: Nomura highlights strong Zydus growth, Lupin and Cipla see sales decline in AprilBusiness Upturn• 8m ago